Arcus Biosciences

Leah's life can look chaotic from the outside – four kids, a career and a #KidneyCancer diagnosis. But perspective changes everything. From where she stands, she sees growth, strength, advocacy and community. Learn more about Leah’s story and explore the #PortrAItsofCancer gallery: https://bit.ly/4htFnXX #KidneyCancerAwarenessMonth

Arcus’s CEO Terry Rosen and COO Jennifer Jarrett will join a fireside chat tomorrow morning hosted by Peter Lawson, D.Phil. (Oxon) at the Barclays 27th Annual Global Healthcare Conference in Miami Beach. Tune in to the live webcast here: https://bit.ly/3QY9awR

Team Arcus showed up on Friday decked out in blue in honor of #DressInBlueDay 💙, a day to raise awareness for #ColorectalCancer and stand with those who have been impacted. Take control of your health and learn from our partners Colorectal Cancer Alliance about how you can get screened; early detection is the best chance for a cure. https://bit.ly/4iKyJNL #ColorectalCancerAwarenessMonth

Tomorrow morning, our CEO Terry Rosen and COO Jennifer Jarrett will participate in a fireside chat hosted by Daina Graybosch at the Leerink Partners Global Healthcare Conference in Miami Beach. You can join the live webcast here: https://bit.ly/4bDUaO8

#Adenosine is a molecule that can be found at high levels in tumors and suppresses the immune system’s ability to fight cancer. At #AACRIO25, our President, Juan Jaen, presented new potential treatment avenues that inhibit adenosine activity and may help improve clinical outcomes in #ColorectalCancer and #PancreaticCancer. Learn more about our research: https://bit.ly/4h5AvrF

Being diagnosed with #stomachcancer felt like a labyrinth, but Melani found her way and her purpose. Now more than 15 years later, she’s lighting a path for others as a mentor with Debbie's Dream Foundation: Curing Stomach Cancer. Honored to showcase #PortrAItsofCancer at #DDFAdvocacyDay2025 this week and connect with the stomach #cancer community gathering in Washington DC to advocate for research, prevention and early detection. Learn more about Melani’s story: https://bit.ly/3QxANg1

We're reporting our fourth-quarter and full-year financial results as well as an update on our clinical-stage pipeline: https://bit.ly/41iuPEC

Today we announced that Arcus will retain the rights to casdatifan, our potential best-in-class HIF-2a inhibitor for the treatment of #kidneycancer, and shared pricing of $150 million common stock offering. This financing is expected to fund Arcus through the anticipated data readout for PEAK-1, the Phase 3 trial for casdatifan in patients with clear cell renal cell carcinoma who have previously received anti-PD-1 therapy. Read the news here: https://bit.ly/3X2tL6E

Understanding new ways to pursue established cancer targets is essential to improve how we can treat the disease. At ASCO #GU25 this weekend, we presented data from our ARC-20 study evaluating a differentiated investigational HIF-2a inhibitor for the treatment of #kidneycancer. Learn from our Senior Director of Medicinal Chemistry Ken Lawson about how casdatifan works to inhibit cancer cell growth: https://bit.ly/3D3lkkE

New clinical data for casdatifan were presented today in a rapid oral session at the ASCO #GU25 Symposium. These data support the potential for our investigational molecule casdatifan to be a best-in-class HIF-2a inhibitor to treat metastatic #kidneycancer. Read more about the data that was presented: https://bit.ly/4gGo5Gr